BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lebacle C, Pooli A, Bessede T, Irani J, Pantuck AJ, Drakaki A. Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art. World J Urol 2019;37:115-23. [PMID: 29858701 DOI: 10.1007/s00345-018-2355-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Chen P, Bi F, Tan W, Jian L, Yu X. A novel immune-related model to predict prognosis and responsiveness to checkpoint and angiogenesis blockade therapy in advanced renal cancer. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.1127448] [Reference Citation Analysis]
2 Tully KH, Berg S, Paciotti M, Janisch F, Reese SW, Noldus J, Shariat SF, Choueiri T, Müller G, McGregor B, Chang SL, Trinh QD, Mossanen M. The Natural History of Renal-Cell Carcinoma with Sarcomatoid Differentiation, a Stage-by-Stage Analysis. Clin Genitourin Cancer 2023;21:63-8. [PMID: 36517393 DOI: 10.1016/j.clgc.2022.11.015] [Reference Citation Analysis]
3 杨 桂. One Case Report of Sarcomatoid Renal Cell Carcinoma. ACM 2023;13:1906-1913. [DOI: 10.12677/acm.2023.132264] [Reference Citation Analysis]
4 Sekino Y, Teishima J, Liang G, Hinata N. Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma. Int J Urol 2022;29:1419-28. [PMID: 36122306 DOI: 10.1111/iju.15042] [Reference Citation Analysis]
5 Vivekanandamoorthy N, Moghadam A, Hort A, Howle J. Malignant small bowel obstruction secondary to metastatic renal cell carcinoma with sarcomatoid transformation. Br J Hosp Med 2022;83:1-3. [DOI: 10.12968/hmed.2021.0626] [Reference Citation Analysis]
6 Takeuchi M, Froemming AT, Kawashima A, Thapa P, Carter RE, Cheville JC, Thompson RH, Takahashi N. Magnetic resonance imaging (MRI) helps differentiate renal cell carcinoma with sarcomatoid differentiation from renal cell carcinoma without sarcomatoid differentiation. Abdom Radiol (NY) 2022;47:2168-77. [PMID: 35381868 DOI: 10.1007/s00261-022-03501-9] [Reference Citation Analysis]
7 Chen T, Zhan X, Du J, Liu X, Deng W, Zhao S, Jiang M, Xiong Y, Zhang X, Chen L, Fu B. A Simple-To-Use Nomogram for Predicting Early Death in Metastatic Renal Cell Carcinoma: A Population-Based Study. Front Surg 2022;9:871577. [DOI: 10.3389/fsurg.2022.871577] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Fontes-Sousa M, Magalhães H, Oliveira A, Carneiro F, Dos Reis FP, Madeira PS, Meireles S. Reviewing Treatment Options for Advanced Renal Cell Carcinoma: Is There Still a Place for Tyrosine Kinase Inhibitor (TKI) Monotherapy? Adv Ther 2022;39:1107-25. [PMID: 35025061 DOI: 10.1007/s12325-021-02007-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Hasan N, Moatasim A. Mucinous tubular and spindle cell carcinoma with high-grade transformation: case report. Surg Exp Pathol 2022;5. [DOI: 10.1186/s42047-022-00105-x] [Reference Citation Analysis]
10 Chen Q, Fu Q, Pu L, Liu X, Liu Y. Effects of HMGA2 gene silencing on cell cycle and apoptosis in the metastatic renal carcinoma cell line ACHN. J Int Med Res 2022;50:3000605221075511. [PMID: 35118889 DOI: 10.1177/03000605221075511] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Bergmann L, Weber S, Hartmann A, Ahrens M. Pathology and systemic therapy of non-clear cell renal cell carcinoma: an overview. Expert Rev Anticancer Ther 2021;:1-14. [PMID: 34291700 DOI: 10.1080/14737140.2021.1959319] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Christensen BR, Hajja YM, Koshkin V, Barata PC. Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell Carcinoma. Curr Treat Options Oncol 2021;22:15. [PMID: 33438115 DOI: 10.1007/s11864-020-00814-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
13 Motzer RJ, Banchereau R, Hamidi H, Powles T, McDermott D, Atkins MB, Escudier B, Liu LF, Leng N, Abbas AR, Fan J, Koeppen H, Lin J, Carroll S, Hashimoto K, Mariathasan S, Green M, Tayama D, Hegde PS, Schiff C, Huseni MA, Rini B. Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. Cancer Cell 2020;38:803-817.e4. [PMID: 33157048 DOI: 10.1016/j.ccell.2020.10.011] [Cited by in Crossref: 173] [Cited by in F6Publishing: 143] [Article Influence: 57.7] [Reference Citation Analysis]
14 Mu L, Guan B, Tian J, Li X, Long Q, Wang M, Wang W, She J, Li X, Wu D, Du Y. MicroRNA‑218 inhibits tumor angiogenesis of human renal cell carcinoma by targeting GAB2. Oncol Rep 2020;44:1961-70. [PMID: 32901879 DOI: 10.3892/or.2020.7759] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
15 Eraslan E, Yalçintaş Ü. Long-term follow-up results of patients with sarcomatoid RCC: A retrospective evaluation of a single center experience. Journal of Surgery and Medicine 2020;4:803-807. [DOI: 10.28982/josam.789516] [Reference Citation Analysis]
16 Zhu H, Zhao S, Zuo C, Ren F. FDG PET/CT and CT Findings of Renal Cell Carcinoma With Sarcomatoid Differentiation. AJR Am J Roentgenol 2020;215:645-51. [PMID: 32755159 DOI: 10.2214/AJR.19.22467] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
17 Zhao Y, Chen H, Xie Y, Zhang C, Hou Y, Jin M. Clinicopathologic features and prognostic factors in patients with renal cell carcinoma with sarcomatoid differentiation. APMIS 2020;128:378-86. [PMID: 32048364 DOI: 10.1111/apm.13035] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
18 Silagy AW, Mano R, Blum KA, DiNatale RG, Marcon J, Tickoo SK, Reznik E, Coleman JA, Russo P, Hakimi AA. The Role of Cytoreductive Nephrectomy for Sarcomatoid Renal Cell Carcinoma: A 29-Year Institutional Experience. Urology 2020;136:169-75. [PMID: 31726184 DOI: 10.1016/j.urology.2019.08.058] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
19 Mano R, Flynn J, Blum KA, Silagy AW, DiNatale RG, Marcon J, Wang A, Sanchez A, Coleman JA, Russo P, Ostrovnaya I, Hakimi AA. The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma. Urol Oncol 2019;37:916-23. [PMID: 31590969 DOI: 10.1016/j.urolonc.2019.09.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
20 Wang YS, Shuang WB, Yin KQ, Tong XN, Xia MC, Yang HS. Analysis of the factors influencing the survival time of patients with sarcomatoid renal cell carcinoma. Mol Clin Oncol 2019;11:405-10. [PMID: 31475069 DOI: 10.3892/mco.2019.1900] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Pichler R, Compérat E, Klatte T, Pichler M, Loidl W, Lusuardi L, Schmidinger M. Renal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope? Cancers (Basel) 2019;11:E422. [PMID: 30934624 DOI: 10.3390/cancers11030422] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
22 Ahrens M, Scheich S, Hartmann A, Bergmann L; IAG-N Interdisciplinary Working Group Kidney Cancer of the German Cancer Society. Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options. Oncol Res Treat 2019;42:128-35. [DOI: 10.1159/000495366] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
23 Alevizakos M, Gaitanidis A, Nasioudis D, Msaouel P, Appleman LJ. Sarcomatoid Renal Cell Carcinoma: Population-Based Study of 879 Patients. Clin Genitourin Cancer 2019;17:e447-53. [PMID: 30799129 DOI: 10.1016/j.clgc.2019.01.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
24 Warren AY, Harrison D. WHO/ISUP classification, grading and pathological staging of renal cell carcinoma: standards and controversies. World J Urol 2018;36:1913-26. [PMID: 30123932 DOI: 10.1007/s00345-018-2447-8] [Cited by in Crossref: 77] [Cited by in F6Publishing: 70] [Article Influence: 15.4] [Reference Citation Analysis]